Publications by authors named "Alice Montoyo"

Claim this Profile
I
Improving Ebola virus disease outbreak control through targeted post-exposure prophylaxis.
Elin Hoffmann Dahl, Placide Mbala, Sylvain Juchet, Abdoulaye Touré, Alice Montoyo

Lancet Glob Health· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of HIV infection and associated factors among female sex workers in Côte d'Ivoire, results of the ANRS 12361 PrEP-CI study using recent infection assays.
Marcellin N Nouaman, Valentine Becquet, Mélanie Plazy, Patrick A Coffie, Clémence Zébago, Alice Montoyo

PLoS One· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV stigma limits the effectiveness of PMTCT in Guinea: the ANRS 12344-DIAVINA study.
Guillaume Breton, Oumou Hawa Diallo, Mohamed Cissé, Oumou Hawa Diallo, Néné Aissatou Diallo, Alice Montoyo

J Antimicrob Chemother· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A community-based healthcare package combining testing and prevention tools, including pre-exposure prophylaxis (PrEP), immediate HIV treatment, management of hepatitis B virus, and sexual and reproductive health (SRH), targeting female sex workers (FSWs) in Côte d'Ivoire: the ANRS 12381 PRINCESSE project.
Valentine Becquet, Marcellin Nouaman, Mélanie Plazy, Aline Agoua, Clémence Zébago, Alice Montoyo

BMC Public Health· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial).
Marwân-Al-Qays Bousmah, Marie Libérée Nishimwe, Tamara Tovar-Sanchez, Martial Lantche Wandji, Mireille Mpoudi-Etame, Alice Montoyo

Pharmacoeconomics· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon.
Alexandra Calmy, Tamara Tovar Sanchez, Charles Kouanfack, Mireille Mpoudi-Etame, Sandrine Leroy, Alice Montoyo

Lancet HIV· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis